KR20220166800A - 헥소스형 모노사카라이드 및 이의 유사체를 이용한 바이러스성 감염 치료의 방법 - Google Patents

헥소스형 모노사카라이드 및 이의 유사체를 이용한 바이러스성 감염 치료의 방법 Download PDF

Info

Publication number
KR20220166800A
KR20220166800A KR1020227034683A KR20227034683A KR20220166800A KR 20220166800 A KR20220166800 A KR 20220166800A KR 1020227034683 A KR1020227034683 A KR 1020227034683A KR 20227034683 A KR20227034683 A KR 20227034683A KR 20220166800 A KR20220166800 A KR 20220166800A
Authority
KR
South Korea
Prior art keywords
group
alkyl
hydrogen
coch
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227034683A
Other languages
English (en)
Korean (ko)
Inventor
왈데마르 프리베
이자벨라 포크트
라팔 지엘린스키
스타니슬로 스코라
도날드 피커
월터 클렘프
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
몰컬린 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템, 몰컬린 바이오테크 인코포레이티드 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20220166800A publication Critical patent/KR20220166800A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227034683A 2020-03-16 2021-03-16 헥소스형 모노사카라이드 및 이의 유사체를 이용한 바이러스성 감염 치료의 방법 Pending KR20220166800A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990337P 2020-03-16 2020-03-16
US62/990,337 2020-03-16
PCT/US2021/022622 WO2021188586A1 (en) 2020-03-16 2021-03-16 Method of treating viral infections with hexose type monosaccharides and analogs thereof

Publications (1)

Publication Number Publication Date
KR20220166800A true KR20220166800A (ko) 2022-12-19

Family

ID=75439533

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034683A Pending KR20220166800A (ko) 2020-03-16 2021-03-16 헥소스형 모노사카라이드 및 이의 유사체를 이용한 바이러스성 감염 치료의 방법

Country Status (11)

Country Link
US (1) US20230130134A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121060A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023518249A (cg-RX-API-DMAC10.html)
KR (1) KR20220166800A (cg-RX-API-DMAC10.html)
CN (1) CN115515601B (cg-RX-API-DMAC10.html)
AU (1) AU2021239927A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018536A2 (cg-RX-API-DMAC10.html)
CA (1) CA3170872A1 (cg-RX-API-DMAC10.html)
IL (1) IL296389A (cg-RX-API-DMAC10.html)
MX (1) MX2022011488A (cg-RX-API-DMAC10.html)
WO (1) WO2021188586A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
ATE544865T1 (de) * 2002-07-12 2012-02-15 Us Gov Health & Human Serv Assays für den zusammenbau von ebola-virus- nukleocapsiden
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
EP1986660A4 (en) * 2006-02-24 2009-08-26 Univ Texas HEXOSE COMPOUNDS FOR CANCER TREATMENT
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
US8927506B2 (en) 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity
US8173636B2 (en) * 2009-04-03 2012-05-08 Achillion Pharmaceuticals, Inc. Hydroxylthienoquinolones and related compounds as anti-infective agents
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
EP3517117A1 (en) * 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Also Published As

Publication number Publication date
JP2023518249A (ja) 2023-04-28
CN115515601A (zh) 2022-12-23
CN115515601B (zh) 2026-06-16
IL296389A (en) 2022-11-01
AU2021239927A1 (en) 2022-10-06
MX2022011488A (es) 2023-03-01
EP4121060A1 (en) 2023-01-25
BR112022018536A2 (pt) 2022-11-29
US20230130134A1 (en) 2023-04-27
WO2021188586A1 (en) 2021-09-23
CA3170872A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
US20120276108A1 (en) Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
US9463189B2 (en) Sulfonyl-substituted bicyclic compounds as PPAR modulators for the treatment of non-alcoholic steatohepatitis
US20230130134A1 (en) Method of treating viral infections with hexose type monosaccharides and analogs thereof
US20090054304A1 (en) Heterocyclic modulators of tgr5 for treatment of disease
US20110275577A1 (en) Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
EP2555776B1 (en) Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure
EP2909216B1 (en) Compositions and methods for improving glucose uptake
US11925654B2 (en) Esters of 2-deoxy-monosaccharides with anti proliferative activity
US20210322396A1 (en) Compositions with synergistic permeation enhancers for drug delivery
JP6408489B2 (ja) 治療配合物（ｃｏｍｐｏｕｎｄｓ）
EP3134417B1 (en) Small molecule analogs of e4orf1
US20120122814A1 (en) Composition for Prevention or Treatment of Hypertrophic Scars or Keloids
HK1214267B (en) Compositions and methods for improving glucose uptake
HK1235406A1 (en) Small molecule analogs of e4orf1
HK1235406B (en) Small molecule analogs of e4orf1
WO2017070235A1 (en) Antitussive compositions and methods
JPWO1990010640A1 (ja) インビボでアロマターゼを阻害する５α―ジヒドロ―１９―ノルエチステロン及びその誘導体を含有する組成物

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000